Cardiovascular diseases and complications in patients with COVID-19

Golukhova E.Z.; Sokolova N.Yu.; Bulaeva N.I.

doi:https://doi.org/10.17116/profmed20202307172

Golukhova E.Z.

Bakulev National Medical Research Center for Cardiovascular Surgery

Sokolova N.Yu.

A.N. Bakoulev Scientific Center for Cardiovascular Surgery;
Tver Regional clinical hospital

Bulaeva N.I.

A.N. Bakoulev Scientific Center for Cardiovascular Surgery

Cardiovascular diseases and complications in patients with COVID-19

Authors:

Golukhova E.Z., Sokolova N.Yu., Bulaeva N.I.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2020;23(7): 72‑77

DOI: 10.17116/profmed20202307172

Read: 4325 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Golukhova EZ, Sokolova NYu, Bulaeva NI. Cardiovascular diseases and complications in patients with COVID-19. Russian Journal of Preventive Medicine. 2020;23(7):72‑77. (In Russ.)
https://doi.org/10.17116/profmed20202307172

Подписка 2026 Профилактическая медицина (Russian Journal of Preventive Medicine)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To analyze available data on cardiovascular disease and complications in patients with COVID-19.

RESULTS

Patients with severe inflammatory response syndrome and «cytokine storm», often accompanied by myocardial damage, are in the highest risk group. In the absence of proven pathogenetic therapy, supporting the treatment and identification of patients with high risk of heart complications is essential.

CONCLUSION

The article describes the basic mechanisms of coronavirus SARS-CoV-2 exposure, the main clinical manifestations and possible mechanisms of heart complications in patients with COVID-19.

Keywords:

COVID-19

SARS-CoV-2

cardiovascular disease

new coronavirus infection

cardiovascular complications

Authors:

Golukhova E.Z.

Bakulev National Medical Research Center for Cardiovascular Surgery

Sokolova N.Yu.

A.N. Bakoulev Scientific Center for Cardiovascular Surgery;
Tver Regional clinical hospital

Bulaeva N.I.

A.N. Bakoulev Scientific Center for Cardiovascular Surgery

Received:

29.07.2020

Accepted:

09.10.2020

Close metadata

References:

Frieman M, Heise M, Baric R. SARS Coronavirus and Innate Immunity. Virus Research. 2008;133(1):101-112. https://doi.org/10.1016/j.virusres.2007.03.015
Marik P. COVID Care Protocol. EVMS: Virginia Medical School; 2020. Accessed October 14, 2020. https://www.evms.edu/covid-19/medical_information_resources/
Zhu H, Rhee J-W, Cheng P, Waliany S, Chang A, Witteles RM. Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response. Curr Cardiol Rep. 2020;22(5):32. https://doi.org/10.1007/s11886-020-01292-3
Golukhova EZ, Sokolova NYu, Bulaeva NI. New coronavirus infection COVID-19: the view of cardiologists. Creative cardiology. 2020;14(1):5-15. (In Russ.). https://doi.org/10.24022/1997-3187-2020-14-1-5-15
Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. European Respiratory Journal. 2020;55(4):2000607. https://doi.org/10.1183/13993003.00607-2020
Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, Li WW, Li VW, Mentzer SJ, Jonigk D. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in COVID-19. N Engl J Med. 2020;383(2):120-128. https://doi.org/10.1056/NEJMoa2015432
Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, Cani DS, Cerini M, Farina D, Gavazzi E, Maroldi R, Adamo M, Ammirati E, Sinagra G, Lombardi CM, Metra M. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):819-824. https://doi.org/10.1001/jamacardio.2020.1096
ESC. Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. ESC: European Heart Journal; 2020. https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance
Liang W, Liang H, Chen A, Chen XuG, Guo H, Ou Limin, Chen B, Li C, Li Y, Guan W, Sang L, Lu J, Xu Y, Chen G, Guo J, Chen Z, Zhao Y, Li S, Zhang N, Zhong N, He J; China Medical Treatment Expert Group for COVID-19. Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients with COVID-19. JAMA Intern Med. 2020;180(8):1081-1089. https://doi.org/10.1001/jamainternmed.2020.2033
Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Der Nigoghossian C, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. Journal of the American College of Cardiology. 2020;75(23):2950-2973. https://doi.org/10.1016/j.jacc.2020.04.031
Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, Holley AB, Jimenez D, Le Gal G, Rali P, Wells P. Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report. Chest. 2020;158(3):1143-1163. https://doi.org/10.1016/j.chest.2020.05.559
Doyen D, Moceri P, Ducreux D, Dellamonica J. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes. Lancet. 2020;395:1516. https://doi.org/10.1016/S0140-6736(20)30912-0
Schilling JD, Ravichandran AK, Mandras SA. Feature. Management of the Hospitalized COVID-19 Patient With Acute Cardiomyopathy or Heart Failure. AMC; 2020. Accessed October 14, 2020. https://www.acc.org/latest-in-cardiology/articles/2020/04/16/14/42/management-of-the-hospitalized-covid-19-coronavirus-2019-patient-with-acute-cardiomyopathy-or-heart-failure
Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811-818. https://doi.org/10.1001/jamacardio.2020.1017
European Centre for Disease Prevention and Control. Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children — 15 May 2020. ECDC: Stockholm; 2020.
Sapp JL, Alqarawi W, MacIntyre CJ, Tadros R, Steinberg C, Roberts JD, Laksman Z, Healey JS, Krahn AD. Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society. Can J Cardiol. 2020;36(6): 948-951. https://doi.org/10.1016/j.cjca.2020.04.003
Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, Patti W, Kirkwood J, Muse A, De Hovitz J, Blog DS, Hutton B, Holtgrave DR, Zucker HA. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in NewYork State. JAMA. 2020;323(24):2493-2502. https://doi.org/10.1001/jama.2020.8630
Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. https://doi.org/10.1016/S0140-6736(20)31180-6
Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. Statement from the Chief Investigators of the Randomised Evaluation of COVID-19 therapy (RECOVERY). Trial on dexamethasone; 2020. Accessed October 14, 2020. https://www.recoverytrial.net/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19
Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P, Metallidis S, Sianos G, Baltagiannis S, Panagopoulos P, Dolianitis K, Randou E, Syrigos K, Kotanidou A, Koulouris NG, Milionis H, Sipsas N, Gogos C, Tsoukalas G, Olympios CD, Tsagalou E, Migdalis I, Gerakari S, Angelidis C, Alexopoulos D, Davlouros P, Hahalis G, Kanonidis I, Katritsis D, Theofilos K, Manolis AS, Michalis L, Naka KK, Pyrgakis VN, Toutouzas KP, Triposkiadis F, Tsioufis K, Vavouranakis E, Martinèz-Dolz L, Reimers B, Stefanini GG, Cleman M, Goudevenos J, Tsiodras S, Tousoulis D, Iliodromitis E, Mehran R, Dangas G, Stefanadis C; GRECCO-19 investigators. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19. JAMA Netw Open. 2020;3(6):e2013136. https://doi.org/10.1001/jamanetworkopen.2020.13136
Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nature Medicine. 2005;11(8):875-879. https://doi.org/10.1038/nm1267
Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, Hausvater A, Newman JD, Berger JS, Bangalore S, Katz SD, Fishman GI, Kunichoff D, Chen Y, Ogedegbe G, Hochman JS. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of COVID-19. N Engl J Med. 2020; 382(25):2441-2448. https://doi.org/10.1056/NEJMoa2008975
Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-Angiotensin-Aldosterone System Blockers and the Risk of COVID-19. N Engl J Med. 2020;382(25):2431-2440. https://doi.org/10.1056/NEJMoa2006923